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Abstract 
Metastasis (spread of cancer cells) is the major cause of cancer related deaths. The reason 
why cancer cells spreads is largely unknown, but proteinases have been suggested to take part 
in this process. The proteinases have also emerged as promising to utilize in cancer therapy. 
However, the lack of pre-established knowledge has previously led to failure in clinical trials, 
e.g. inhibitors against matrix metalloproteinases (MMPs) caused severe side effects in 
patients. The cysteine proteinase legumain is overexpressed in many solid human tumors, and 
overexpression is associated with enhanced metastasis. Currently, the knowledge about 
subcellular localization, trafficking and requirements for legumain activation remains largely 
unexplored. Known factors that influence the transport and activation of proteins in general 
are glycosylation and phosphorylation. Both of the aforementioned modifications have been 
demonstrated on legumain, but the functional role remains unknown.  
In this study, we investigated processing and localization of legumain after manipulation of 
glycosylation and phosphorylation. The colorectal cell lines HCT116 and SW620 were used 
as cell models. N-linked glycosylation was inhibited by the biochemical tool tunicamycin, 
whereas phosphorylation was blocked by staurosporine or H7. Legumain expression, 
processing and distribution were analyzed by immunoblotting and confocal microscopy.  
The results have shown that processing of legumain to the mature active form was totally 
absent after tunicamycin treatment. It was also identified that tunicamycin resulted in a 
decreased nuclear transport, whereas legumain secretion was apparently not affected. 
Furthermore, treatment with staurosporine changed the cell morphology, but this was not 
observed after optimizing the experiment with H7. However, neither staurosporine nor H7 
seemed to exert influences on legumain expression or processing.  
Overall the results imply that glycosylation, but not phosphorylation, is essential for legumain 
processing. Furthermore, glycosylation affects legumain transport to the nucleus, but not to 
the extracellular environment. However, additional research needs to be done to conclude 
how glycosylation affects intracellular legumain transport.  
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Abbreviations   
AEP  Asparaginyl endopepsidase 
ALP  Alkaline phosphatase 
ARSB  Arylsulfatase B 
Asn  Asparagine 
BCA  Bicinchoninic acid 
CaCl2  Calcium chloride 
CEB   Cytoplasmic extraction buffer 
CRC  Colorectal cancer 
DAPI  4',6-diamidino-2-phenylindole 
ddH20  Double distilled water 
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2 
 
NEB  Nuclear extraction buffer 
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PEB  Pellet extraction buffer 
PES  Phenazine etosulfat 
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RPMI  Roswell Park Memorial Institute medium 
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SDS  Sodium dodecyl sulfate 
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TBST  Tris-Buffered Saline with Tween 20 
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1 Introduction 
1.1 General principles of cancer 
Cancer is a collective term of a large group of genetic conditions initiated by uncontrolled cell 
growth. Normally, there is a balance between genes that promote- and suppress cell 
proliferation. However, some of these genes can be subjected to mutations which cause 
uncontrolled cell multiplication, and the cells lose their original functions. As the division 
continues there will be an accumulation of cancer cells in a limited area, giving rise to a 
primary tumor (Norwegian Electronic Legehåndbok, 2014).  
  
 
 
 
 
 
 
 
Figure 1.1: Hallmarks of cancer. The figure illustrates the six acquired hallmarks during cancer development 
(Hanahan et al., 2011).  
Cancer evolves progressively, and the complexity of neoplastic diseases may be summarized 
by six acquired biological capabilities, also known as hallmarks of cancer (Fig. 1.1). These 
capabilities, that distinguish cancer from normal cells, includes sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative immorality, 
inducing angiogenesis and activating invasion and metastasis (Hanahan et al., 2011).  
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1.2 Invasion and metastasis  
Metastasis is the major cause of cancer-related deaths, and constitutes a major problem for 
cancer therapy. Metastasis is a multistage process, commonly termed the invasion-metastasis 
cascade, during which cells spread from the primary tumor via blood and lymphatic vessels to 
distant anatomical organ sites. Cancer cells that metastasize have undergone a series of 
genetic alterations, and the process is initiated by local invasion, which is entry of cancer cells 
from the primary tumor into the adjacent normal tissues (Fig. 1.2). A small proportion of 
these cells may end up circulating in the blood or lymphatic system. An even smaller fraction 
of these circulating tumor cells may eventually extravasate at a distant location and start 
dividing. The end product of the invasion-metastasis cascade is secondary tumors, also known 
as metastases (Talmadge et al., 2010, Valastyan et al., 2011).  
 
 
 
 
 
 
 
 
Figure 1.2: The invasion-metastasis cascade. The figure shows the main steps in the formation of metastases 
(Valastyan et al., 2011).   
1.3 Colorectal cancer 
1.3.1 Prevalence 
Colorectal cancer (CRC) is the third most common cancer worldwide, and is the fourth most 
frequent cause of cancer death affecting both sexes (Weitz et al., 2005, Ferlay et al., 2010). In 
  5 
 
Norway, CRC is the fourth frequent cancer and the second frequent cause of cancer death 
(both sexes) (Cancer Registry of Norway, 2011). 
1.3.2 Pathogenesis and risk factors  
Colorectal cancer is a disease of the colon or rectum, and begins in the epithelial cells in the 
innermost layer (mucosa) of the large intestine. Underneath this mucosa layers lies the 
submucosa, which contains blood and lymphatic vessels. If the cancer cells invade into the 
submucosa, it can gain entrance to the blood supply, permitting spread throughout the body 
(Frayling, 2001, Yeatman, 2001).  
The majority of colorectal cancers arise sporadically, and the risk factors involves increasing 
age, male sex, unhealthy lifestyle, smoking, etc. (Weitz et al., 2005). However, approximately 
20 % of CRC patients are estimated to have some component of familiar risk (Lynch et al., 
2003).  
1.4 Proteinases 
Proteinases are specialized enzymes which catalyze the cleavage of proteins by hydrolysis. In 
the literature, proteinases are also known as proteases, proteolytic enzymes and peptidases 
(Barrett, 2001, Barrett et al., 2013). More than 600 proteinases have been identified and they 
are classified based upon their distinct catalytic mechanism for substrate hydrolysis, into 
aspartic, cysteine, glutamic, metallo, threonine and serine proteinases. Proteinases can be 
subdivided into endopeptidases or exopeptidases, reflecting their cleaving position in the 
polypeptide chain. Endopeptidases cleave internal bonds in the polypeptide, while 
exopeptidases act near the N- or C-terminal end of the polypeptide chain (Chwieralski et al., 
2006, Turk, 2006, Barrett et al., 2013). In the modern classification system, MEROPS peptide 
database, proteinases are dived into families and clans based upon the structural similarities. 
Individual proteinases are grouped into families on the basis of the similarities in the amino 
acid sequences. The families, which most likely share a common origin, are further grouped 
together in a clan (Barrett, 2001, Barrett et al., 2013).   
The primary role of proteinases were long considered to be digestion of food and protein 
turnover. However, proteinases have also been found to be important signal molecules that 
are involved in numerous vital processes, such as immune responses, cell proliferation, cell 
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death and DNA replication. Proteinase signaling pathways are strictly regulated, and aberrant 
regulation of proteinase activity may contribute to pathologies such as cancer (Barrett, 2001, 
Turk, 2006, López-Otín et al., 2008).  
1.5 Legumain 
Legumain is a cysteine endopepsidase which belongs to the C13 peptidase family of clan CD 
(Fig. 1.3) (Rawlings et al., 2014). It was originally discovered and isolated from plants and a 
blood fluke, before  Chen et al. described the mammalian version (Chen et al., 1997). 
Legumain shows strict specificity for hydrolysis of peptide bonds at the C-terminal side 
(position P1) of asparaginyl in substrates and, to a lesser extent, after aspartic acid at low pH 
(Chen et al., 1997, Halfon et al., 1998). In the literature, legumain is synonymously termed 
asparaginyl endopepsidase (AEP), reflecting its strict specificity and function (Li et al., 2003). 
The proteinase cathepsin B, H and L are examples of substrates that are processed by 
legumain (Shirahama-Noda et al., 2003), and the most potent endogenous inhibitors are 
cystatin C (Ki 0.20 nM) and cystatin E/M (Ki 0.0016 nM) (Alvarez-Fernandez et al., 1999). 
Legumain is primarily localized in the late endosomes and lysosomes, in conjunction with the 
acidic environment which is considered to be favorable for proteolytic activity (Chen et al., 
1998). In addition, proteolytic active legumain has also been observed in the nucleus and 
prolegumain in the extracellular environment (Haugen et al., 2013). 
In non-disease mammalian tissues, legumain is predominantly found in the kidney and 
placenta. Moreover, legumain expression and enzymatic activity is also detected in the spleen, 
liver, thymus and testis, although to a lesser extent (Chen et al., 1997, Chen et al., 1998).  
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Figure 1.3: Classification of legumain. 
1.5.1 Legumain activation 
Legumain is translated as an inactive proenzyme of 56 kDa termed prolegumain. How this 
proteinase itself is activated is not fully characterized, but a multi-step process is thought to 
involve both autocatalytic processing at different pH thresholds, as well as involvement of 
other proteinases (Li et al., 2003).  
Full length prolegumain of 56 kDa is stable and enzymatically inactive at neutral pH. One 
theory is that once the pH is lowered below 5.5, an autocatalytic cleavage of the C-terminal 
domain is initiated, resulting in an inactive intermediate of 47 kDa (Fig. 1.4). A further 
decrease in pH triggers the release of the N-terminal propeptide and produces an active 
intermediate of 46 kDa. In vivo, the 46 kDa intermediate is further processed to the fully 
active form of 36 kDa by the involvement of other lysosomal proteinases (Li et al., 2003). 
Recent results demonstrate that the complex maturation process may be reversed (Zhao et al., 
2014).  
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Fig 1.4: Suggested scheme for legumain activation. Upon pH lowering, the inactive proenzyme of 56 kDa is 
progressively converted to 47 kDa (inactive) and to 46 kDa (active) legumain. In vivo, the 46 kDa intermediate is 
further processed to the fully active form of 36 kDa by other lysosomal proteinases (adapted from (Li et al., 
2003)).  
1.5.2 Cellular functions of legumain 
Legumain is up-regulated in the majority of human solid tumors, such as colorectal, prostate 
and breast cancers (Liu et al., 2003). In tumor cells, legumain is localized both intracellularly 
and on the cell surface. Intracellular legumain is predominantly distributed in the membrane- 
associated vesicles i.e. Golgi, endosomes and lysosomes (Liu et al., 2003, Murthy et al., 
2005), nevertheless, the proteinase does not seem to be exclusively confined to these 
subcellular structures. Most recently, Haugen et al. demonstrated legumain expression and 
proteolytic activity in the nucleus of CRC cells. However, the biological function of active 
legumain in the nucleus has not yet been elucidated (Haugen et al., 2013).  
Legumain has been shown to facilitate cell migration, and overexpression in tumors is 
associated with enhanced invasion and metastasis (Liu et al., 2003). These properties might 
be in connection with legumain being shown to activate the matrix metalloproteinase (MMP) 
progelatinase A in cultured cells (Chen et al., 2001). It has been hypothesized that tumors that 
express high levels of legumain would display a more aggressive behavior and result in a poor 
prognosis, which has been confirmed in CRC (Liu et al., 2003, Murthy et al., 2005). 
Other known important cellular functions of legumain is within the immune system where it 
has been shown to process microbial antigens for MHC class II  presentation, and assist in 
proteolytic maturation of Toll-like receptor 9 (Manoury et al., 1998, Sepulveda et al., 2009). 
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Legumain has also been associated with atherosclerosis (Clerin et al., 2008), stroke (Liu et 
al., 2008) and to be involved in bone resorption as it inhibits osteoclast formation (Choi et al., 
1999).  
1.6 Utilizing proteinases in prodrug activation in 
cancer therapy 
Current compounds used in cancer medicine are generally not very specific and cause 
undesirable cytotoxicity to normal cells. A promising approach to increase selectivity is to 
exploit physiological conditions of the target tissue that differs greatly from that of other 
tissues. Proteinases are upregulated in many human tumors. The high levels in tumor cells 
coupled with their ability to cut specific substrates (amino acid sequences) makes proteinases 
attractive candidates for selective prodrug activation in cancer therapy (Mahato et al., 2011, 
Choi et al., 2012). Prodrugs are inactive derivatives of active drug molecules that must 
undergo a conversion in vivo to exert their pharmacological effect, e.g. by utilizing 
proteinases (Huttunen et al., 2011, Choi et al., 2012). 
Adcetris ® (brentuximab vedotin)  is an example of an approved prodrug against lymphoma, 
that utilizes the proteinase cathepsin B for activation (Katz et al., 2011). Legumain shows (as 
previously mentioned) restricted specificity C-terminally to asparagine, and is to date the only 
known human proteinase with this specificity (Chen et al., 1997, Dando et al., 1999). Because 
of this strict substrate specificity and high-level expression in many human tumors, legumain 
represent a highly relevant proteinase which can be utilized for prodrug activation in selective 
cancer treatment (Liu et al., 2003). It has been done several preclinical studies where high 
potent chemotherapeutics (e.g. doxorubicin, auristatin, dolastatin) have been masked with a 
peptide that is cleaved in the presence of legumain (Fig. 1.5) (Liu et al., 2003, Bajjuri et al., 
2011, Liu et al., 2012). However, former unsuccessful clinical trials have shown that detailed 
knowledge about proteinases, such as function and localization, are essential for development 
of  proteinase-activated  prodrugs (Turk, 2006, Choi et al., 2012).  
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Figure 1.5: A proteinase-activated prodrug strategy. Incorporating of a legumain masking sequence onto 
high potent chemotherapeutics is a promising approach to increase the selectivity of cancer therapy. 
1.7 Protein modifications 
Structural modifications of proteins can occur either during synthesis, cotranslational 
modifications, or after synthesis, posttranslational modifications (Shandala et al., 2001). 
Protein modifications have been shown to be essential in cell regulation because they can 
potentially influence chemical properties, stability, activity and cellular location of proteins. 
There have been identified over 400 protein modifications, where phosphorylation and 
glycosylation are among the most common and well-studied (Sparbier et al., 2005, Farley et 
al., 2009). 
1.8 Protein glycosylation 
Protein glycosylation, which is covalent attachment of sugar moieties to polypeptides, is an 
important posttranslational modification (Shandala et al., 2001). It is estimated that more than 
half of all mammalian proteins are glycosylated (Apweiler et al., 1999, Zafar et al., 2011). 
Glycosylation is vital for a wide range of biological processes, and has been shown to affect 
enzyme activity, protein localization and stability. There are five main types of glycosylation 
with various carbohydrate structures, but the most abundant are N- or O-linked glycosylation 
(Ohtsubo et al., 2006, Farley et al., 2009, Zafar et al., 2011).  
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1.8.1 N-linked protein glycosylation  
N-linked glycosylation occurs in the rough endoplasmic reticulum (RER), and involves the 
attachment of high-mannose oligosaccharide structures to selected asparagine (Asn)  residues 
in the polypeptide backbone (Shandala et al., 2001).  
The high mannose oligosaccharide structure, containing a total of 14 sugars, is synthesized by 
a sequential process. The biosynthesis commences on the cytoplasmic side of the RER and 
terminates at the lumenal face, giving rise to the final oligosaccharide precursor product 
Glc3Man9GlcNAc2-PP-dolichol. In the lumen of RER, the completed oligosaccharide 
structure is then transferred en bloc to selected Asn residues as nascent proteins are being 
translocated into the RER (Kornfeld et al., 1985, Shandala et al., 2001). Asparagine acceptors 
that are glycosylated are always present in the tripeptide sequence N-X-S/T, where N is 
asparagine, X is any amino acid except proline and S/T are, respectively, serine or threonine. 
However, the presence of this consensus tripeptide motif appears to be necessary but not 
sufficient for the protein to serve as an acceptor in vivo (Pless et al., 1977, Kornfeld et al., 
1985). 
 
Figure 1.6: Structures of the major types of N-linked oligosaccharides (adapted from (Shandala et al., 
2001)).  
Once the glycosylation has occurred, the oligosaccharide precursor is subjected to a variety of 
processing and modifications in the RER and Golgi apparatus. This elaboration of the 
oligosaccharide leads formation of one of the three main types of N-linked oligosaccharide 
structure, termed “high mannose”, “hybrid” and “complex” (Fig 1.6) (Kornfeld et al., 1985, 
Shandala et al., 2001). The potential for diversity in the composition of oligosaccharides that 
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can be attached to the protein and remodeling of the sugar chain can result in heterogeneity of 
the end-stage glycoproteins (Shandala et al., 2001, Aebi, 2013).  
1.8.2 Legumain and N-linked glycosylation 
The glycosylation pattern of legumain in two colorectal cells, HCT116 and SW620, has 
previously been investigated (Haugen et al., Dept. of Tumor Biology, Oslo University 
Hospital), and the protein band size of the unglycosylated forms of legumain was observed 
(Fig. 1.7 B). The CRC cell lines were treated with PNGase F, an enzyme which removes N-
linked glycosylation (see chapter 1.8.4), and analyzed by gel electrophoresis (4-12 % gradient 
gel) and immunoblotting of legumain. First, the immunoblot demonstrated a noticeable mass 
shift in both cell lines after PNGase F treatment from 56 kDa to approximately 47 kDa for the 
proform and from 36 kDa to 28 kDa for the mature active form of legumain. This indicates 
that legumain is subjected to N-linked glycosylation (Fig. 1.7). Second, incomplete PNGase F 
treatment of HCT116 cells gave rise to three distinct bands located below the glycosylated 36 
kDa band in the control, which demonstrated that least three of the four potential 
glycosylation sites in legumain are occupied (Fig. 1.7)  (Haugen et al., unpublished data).  
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Figure 1.7: N-linked glycosylation of legumain. (A) Legumain expression in HCT116 and SW620 cell lysates 
when deglycosylated by treatment with PNGase F (Haugen et al., unpublished data). (B) Estimated protein band 
sizes of the glycosylated and unglycosylated forms of legumain. (C) The potential glycosylation sites (red) on 
asparagine (N) acceptors in legumain. 
1.8.3 Tunicamycin, an inhibitor of N-linked glycosylation 
Tunicamycin is a nucleoside antibiotic isolated from Streptomyces lysosuperificus (Takatsuki 
et al., 1971). Tunicamycin specifically inhibits the first step in the biosynthesis of the high 
mannose oligosaccharide, i.e. the transfer of GlcNac-1-P to the specialized lipid dolichol 
phosphatase (Dol-P). If this step is inhibited in vivo, the oligosaccharide cannot be formed and 
the glycosylation of a protein is prevented. Moreover, the inhibitory action of tunicamycin 
seems to be restricted exclusively to the transfer of the GlcNAc moiety, whereas further 
glycosyl transfer reactions are not affected (Tkacz et al., 1975, Lehle et al., 1976, Heifetz et 
al., 1979). 
Tunicamycin is a powerful experimental tool for studying the role of glycoproteins in a wide 
range of biological systems (Heifetz et al., 1979). Working as a competitive tight-binding 
inhibitor, the concentration described to prevent glycosylation varies between 0.1 - 10 µg/ml 
(Elbein, 1987). The treatment time in vivo has been suggested to be 24 hours, which may 
permit a cell to replace many endogenous glycoproteins with proteins synthesized in the 
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presence of tunicamycin. However, for proteins with a slower or faster turnover than average, 
longer or shorter incubation times may be appropriate (Powell, 2001).There are several 
cautions that should be taken into account using tunicamycin in biochemical studies, 
especially its toxic effect. Tunicamycin can inhibit cell division in vitro by arrest cells in G1 
of the cell cycle. However, not all cell systems are sensitive (Savage et al., 1983, Elbein, 
1987). 
1.8.4 PNGase F and Endo H 
Peptide -N-glycosidase F (PNGase F) and endoglycosidase H (Endo H) are enzymes which 
are used as biochemical research tools for protein deglycosylation (Kuhn et al., 1994, O'Neill, 
1996). PNGase F removes all types of oligosaccharides (high mannose, hybrid or complex) 
(Fig. 1.6) from proteins. This enzyme cleaves the bonds between the innermost 
oligosaccharide and the amino acid sequence, making the protein of interest fully 
deglycosylated (Kuhn et al., 1994). Endo H is a highly specific endoglycosidase, which 
cleaves within the core of the oligosaccharide and removes primarily high mannose 
oligosaccharides, and to some extent, hybrid oligosaccharides from proteins. This enzyme can 
be used to determine the type of N-linked glycosylation (O'Neill, 1996).   
1.9 Protein phosphorylation 
Protein phosphorylation is a reversible protein modification, and involves the covalent 
attachment of a phosphate group to an amino acid in the target protein. The amino acid 
residue(s) to which the phosphate group is transferred is usually a serine, threonine or 
tyrosine, but histidine or lysine residues have also been found to be phosphorylated. Protein 
phosphorylation and dephosphorylation are catalyzed by protein kinases and protein 
phosphatases, respectively (Krebs et al., 1979, Hunter, 1989, Graves et al., 1999). It has been 
estimated that 30 % of the human proteome is phosphorylated, and the reversible process has 
been shown to have a regulatory role in a multitude of cellular processes such as proliferation, 
migration, protein transcription and apoptosis (Cohen, 2001, White, 2008, Farley et al., 2009). 
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1.9.1 Legumain and phosphorylation 
Legumain phosphorylation has recently been investigated in the colorectal cell line HCT116 
(Haugen et al., Dept. of Tumor Biology, Oslo University Hospital). The cell line was treated 
with alkaline phosphatase (ALP), which removes phosphate groups from proteins, and 
analyzed by 2D gel electrophoresis and immunoblotting of legumain. In comparison to the 
control lysates, removal of the phosphate group using ALP resulted in a visible shift towards 
the anionic end (Fig. 1.8 A). This indicates that the charge of the protein has been modified, 
and thus that legumain has been de-phosphorylated. In silico analysis (computer simulation) 
predicted that there were totally 15 potential phosphorylation sites at the serine (S), threonine 
(T) and tyrosine (Y) residues in legumain (Fig. 1.8 B) (Blom et al., 1999). However, which of 
the predicted phosphorylation sites that are occupied or the function of these phosphorylations 
have not been elucidated (Haugen et al., unpublished data).  
 
Figure 1.8: Phosphorylation of legumain. (A) The cell lysates were treated with (lower panel) or without 
(upper panel) ALP and analyzed by 2D gel electrophoresis and immunoblotting of legumain. The protein pattern 
in the cell lysate treated with ALP compared to the control showed a clear shift towards the anionic end, which 
demonstrated removal of phosphate groups on legumain (Haugen et al., unpublished data). (B) Predicted 
phosphorylation sites on the serine (S), threonine (T) and tyrosine (Y) amino acid sequences in legumain using 
NetPhos 2.0 method, which have a sensitivity in the range from 69-96 % (Blom et al., 1999). 
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1.9.2 Protein kinases 
The protein kinases make up a large family of homologous protein which perform protein 
phosphorylation (Hanks et al., 1995). As phosphorylation has a regulatory role in many 
cellular processes, it has been a growing interest in developing specific inhibitors of protein 
kinases for clinical use (Cohen, 2002).   
Protein kinases are generally classified into two broad classes, protein serine/threonine 
kinases (PSK) and protein tyrosine kinases (PTK), on the basis of the amino acids 
phosphorylated in their protein substrates. Protein kinases can further be grouped into 
subfamilies based on overall similarities in the catalytic domain sequences. The individual 
members are grouped together primary on the basis of their similar catalytic domain 
sequence. The protein kinase C (PKC) referred to in chapter 1.9.3 and 1.9.4 is member of the 
protein serine/threonine kinases (PSK) (Hanks, 1991, Hanks et al., 1995). 
1.9.3 Staurosporine, a broad spectrum protein kinase inhibitor  
Staurosporine is an alkaloid isolated from Streoptomyces staurosporeus (Omura et al., 1977). 
Staurosporine is a cell permeable compound and is potent inhibitor of protein kinase C (PKC) 
with an IC50 value in the nanomolar range (Tamaoki et al., 1986). In addition, staurosporine is 
also an inhibitor of a variety of other protein kinases in vitro in a rather nonspecific manner 
(Ruegg et al., 1989). Staurosporine has shown to exhibit strong cytotoxic effects at 
micromolar concentrations, and to induce apoptosis in a variety of cells using concentrations 
in a wide range (100 nmol/L-100 µmol/L) (Tamaoki et al., 1986, Zhang et al., 2003).  
1.9.4 H7, a narrow spectrum protein kinase inhibitor  
H7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine) is a reversible and selective protein 
kinase inhibitor. H7 has highest potency towards protein kinase C (PKC), compared to other 
kinases, with a Ki  value of 6 µM. H7 is a synthetic compound, and serve as a useful 
pharmacological tool for elucidation of protein phosphorylation (Hidaka et al., 1984).  
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2 Aims of the present study 
The aim of the present project is to investigate whether pharmacological manipulation of 
legumain modifications like phosphorylation and glycosylation will influence legumain 
activation and subcellular transport. To test these hypotheses legumain expression and 
distribution in the CRC cell lines HCT116 and SW620 cells will be characterized after 
treatment with tunicamycin (an inhibitor of N-linked glycosylation) and various protein 
kinase inhibitors (inhibitors of phosphorylation).  
Specific aims 
1) Identify whether glycosylation influence legumain processing and activation 
2) Study whether glycosylation affects cellular transport of legumain. 
3) Study whether glycosylation is important for legumain secretion. 
4) Identify whether phosphorylation influence legumain processing and activation 
5) Study whether phosphorylation affects cellular transport of legumain.  
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3 Materials and methods 
3.1 Cell lines 
3.1.1 Used cell lines 
Two human colorectal cell lines were used in this study, SW620 and HCT116 (ATCC). 
HCT116 and SW620 cells are both adherent in culture, but have a distinct cellular 
morphology.  
3.1.2 Cell storage  
Cells were frozen and stored over longer periods of time in liquid nitrogen (-196°C), and 
thawed before use. For storage up to 6 months, the cells were frozen and stored at -70°C. To 
limit cell bursting and damage, a freezing solution (Appendix 1.1) containing 10 % of the 
cryoprotective agent dimethyl sulfoxide (DMSO) (Sigma-Aldrich) was added to the cells 
before freezing.  
3.1.3 Thawing and cell culturing 
Frozen cell ampoules with HCT116 and SW620 were thawed and then cultivated in T-75 
flasks (Sigma-Aldrich) with 10 ml pre-warmed culture medium (Appendix 1.2) with or 
without 10 % foetal bovine serum (FBS) (PAA). The cells were grown in a humid 
environment at 37°C with 5 % CO2, and all work with the cells was performed under sterile 
conditions in a LAF (Laminar Air Flow) bench. To remove residues of toxic DMSO (1 %), 
the medium was always replaced with fresh growth medium (Appendix 1.2) 16- 24 hours 
after thawing.  
3.1.4 Passing and counting of cells 
For passing or when seeding cells for experiments, the cells were detached from the growth 
surface using 1 ml trypsin/EDTA (Sigma-Aldrich) and diluted in fresh growth medium with 
serum according to cell density. Media containing serum was used to deactivate 
trypsin/EDTA. One fraction (1 ml) of cell solution was retained in the culturing flask (new 
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flask every third time) and fresh growth medium was added to a total of 10 ml for continued 
culturing. The other fraction was transferred to clean tubes and used for seeding or discarded. 
The cells were passed routinely twice a week to ensure that the cells did not grow too dense.  
The cells were counted automatically before seeding for experiments. Briefly, 10 µl cell 
suspensions were mixed with 10 µl tryphan blue (Life technologies). Furthermore, 10 µl of 
the cell solution were applied into a chamber slide and counted using Countess Automatic 
Cell Counter (Invitrogen). The instrument calculates the total number of cells, including the 
number of live cells and the number of dead cells/ml cell suspension. The number of live 
cells/ml cell suspension was used to adapt the cell concentration and total number of cells 
required for the individual experiments. 
3.2 Treatment of cells with inhibitors 
3.2.1 Seeding of cells 
HCT116 and SW620 cells were seeded (1.5 x 10
5
/ml or 2.0 x 10
5
/ml) in 6-well plates 
(Thermo Scientific) and left overnight for adherence to the plastic surface. The following day, 
the cellular morphology was observed in the microscope (Olympus) and the treatments were 
added directly into the wells. Control cells were always included. A brief description of used 
treatments in the present study follows.  
3.2.2 Treatment with tunicamycin 
Tunicamycin (Calbiochem) stock solution (10 mg/ml) was diluted 1:10 in DMSO, and added 
to the cells to obtain the following final concentrations: 1 µg/ml or 5 µg/ml. The control cells 
were added 10 µl DMSO. To obtain condition cell medium for immunoblotting, the medium 
was replaced with serum-free growth medium the day after seeding with the presences of 
tunicamycin. After incubation for 6, 24 or 48 hours, cells and serum-free conditioned medium 
were harvested (see section 3.3).  
3.2.3 Treatment with staurosporine  
Staurosporine (Calbiochem) stock solution (1mM) was diluted 1:10 in DMSO, and added to 
the cells to obtain the following final concentrations: 0.2, 0.6 or 1 µM.  The control cells were 
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added 10 µl DMSO. The cells were incubated for 0.5 or 6 hours before harvesting (see section 
3.3).   
3.2.4 Treatment with  H7 
H7, dihydrochoride (Calbiochem) stock solution (50 mM) was diluted 1:10 in double distilled 
water (ddH20), and added to the cells to obtain the following final concentrations: 5, 15, or 30 
µM.  The control cells were added 10 µl ddH20. The cells were incubated for 1 hour before 
harvesting ( see section 3.3).  
3.3 Harvesting of cells and conditioned media  
Harvesting of cells and serum-free conditioned media were performed to obtain samples for 
immunoblotting.  
Conditioned media (with serum) were removed, and the adherent cells were carefully washed 
3 times in cold 1 X Phosphate-buffered Saline (PBS) (Lonza). Subsequently, the cells were 
lysed with 75 µl cold lysis buffer (Appendix 2.2) and scraped off by the use of a rubber 
policeman (TPP). The cell lysates were transferred to Eppendorf tubes (Thermo Scientific) 
and centrifuged at 13000 x g for 15 minutes at 4°C. Further, the supernatants were transferred 
to clean tubes on ice. To prevent degradation, the samples were kept on ice and cold 
temperature at all times after cell lysis.  
Serum-free conditioned media were collected and centrifuged at 500 x g for 5 minutes. 
Subsequently, the supernatant were transferred to Eppendorf tubes on ice. Proteins in the 
conditioned medium were concentrated by addition of 4 volumes of ice cold acetone (Merck), 
leaving the sample on ice for 15 min and centrifugation at 4°C and 12000 x g for 10 min. 
Liquid was removed and the precipitate air dried at room temperature before re-dissolving in 
40 µl lysis buffer (Appendix 2.2). Cell lysates and conditioned media were stored at -70°C for 
downstream analysis.  
3.4 PNGase F and Endo H treatment 
Cell lysates treated with tunicamycin or DMSO (control) as described in 3.2.2, were further 
treated by using PNGase F or Endo H kit (New England BioLabs). The experiments were 
  21 
 
performed according to the manufactures protocol. In brief, 20- 40 µg samples were mixed 
with 10 X glycoprotein denaturing buffer (1/10 of total calculated volume) and the reaction 
mix was denatured at 100°C for 10 minutes. The tubes with denatured solution was either 
added 1µl (=500 units) PNGase F, or 1µl (=500 units) Endo H. To the control lysates, 1 µl 
ddh20 were added instead of the enzymes. The reaction mix was finally incubated at 37°C for 
1 hour at gentle mixing before the samples were stored at -70 °C for further analysis.   
3.5 Subcellular enrichment 
Isolation and enrichment of proteins in the cellular fractions cytosol, membrane/lysosomes, 
nucleus and cytoskeletal were performed using the Subcellular Protein Fractionation Kit for 
Cultured Cells (Thermo Scientific). The protocol was followed as recommended by the 
manufacture, additionally washing of the pellet between the first two fractions were 
performed to reduce contamination and to ensure high purity.  
3.5.1 Cell culture preparation 
HCT116 cells were seeded in T-250 flasks (Sigma-Aldrich) one day prior to treatment with 
tunicamycin (5 µg/ml) and DMSO (10 µl). After 24 hours incubation, the cells were detached 
using trypsin/EDTA and suspended in 1 ml cold 1 X PBS. The cell suspension was 
transferred to a 15 ml tube and pelleted by centrifugation at 500 x g for 5 minutes. 
Subsequently, the pellet was resuspended in cold PBS and pelleted by centrifugation at 500 x 
g for 5 minutes. The supernatant were removed, and the last step was repeated (at 4°C).  
3.5.2 Subcellular enrichment 
The fractionation kit contained extraction buffers, proteinase inhibitors, micrococcal nuclease 
and calcium chloride (CaCl2). An overview of the buffers and volume used in this protocol is 
depicted in Table 3.1. The buffers were thawed and added proteinase inhibitor immediately 
before use. Cytoplasmic extraction buffer (CEB), Membrane extraction buffer (MEB) and 
nuclear extraction buffer (NEB) were kept on ice at all times. 
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Table 3.1: Buffer types and volume utilized in subcellular enrichment.  
 
 
Cytoplasmic 
extraction buffer 
(CEB) 
Membrane 
extraction buffer 
(MEB) 
Nuclear 
extraction buffer 
(NEB) 
Pellet extraction 
buffer           
(PEB) 
Used to isolate 
proteins from 
Cytosol Lipid membranes and 
intramembranous 
content 
Nucleus Cytoskeletal 
Volume buffer (µl) 300 300 100 100 
Proteinase inhibitor 
(1:100) (µl) 
3  3  1  1  
 
The cell pellet obtain in section 3.5.1 was resuspended in cold CEB and incubated at 4°C for 
10 minutes on a rotary shaker. Further, the cell suspension was centrifuged at 500 x g for 5 
minutes, and the supernatant (cytoplasmic fraction) was transferred to a clean tube on ice. The 
pellet was washed by adding CEB, centrifugation at 500 x g for 5 minutes before the 
supernatant was removed. Subsequently, the pellet was resuspended in cold MEB, vortexed at 
a high speed and incubated at 4°C for 10 minutes. The suspension containing MEB was 
centrifuged at 3000 x g for 5 minutes, and the supernatant (membrane fraction) was 
transferred to a clean tube on ice. After washing the pellet with MEB, ice cold NEB was 
added to the pellet and then mixed by vortexing. Further, the suspension was incubated at 4°C 
for 30 minutes on a rotary shaker, centrifuged at 5000 x g for 5 minutes before the supernatant 
(soluble nuclear extract) were transferred to a clean tube on ice. Subsequently, room 
temperature NEB (containing 5 µl CaCl2 and 3 µl micrococcal nuclease) was added to the 
pellet and then mixed by vortexing. The suspension was incubated at 15 minutes at room 
temperature, vortexed at a high for 15 seconds and centrifuged 16000 x g for 5 minutes. The 
supernatant (chromatin-bounded nuclear fraction) was transferred to a clean tube on ice. 
Finally, to obtain the cytoskeletal extract, room temperature PEB were mixed with the pellet 
by vortexing, incubated at room temperature for 10 minutes and centrifuged at 16000 x g for 
5 minutes. All the fractions were stored at -70°C for further analysis.  
3.6 Total protein concentration measurements 
The protein concentration of each cell lysates was measured using bicinchoninic acid (BCA) 
protein assay kit (Pierce). This is a colorimetric method based on the biuretic reaction 
(proteins reduce the copper ions from Cu
2+
 to Cu
1+ 
in an alkaline environment) where Cu
1+ 
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forms a purple colored complex with a reagent containing bicinchoninic acid (BCA). The 
BCA/copper complex exhibits strong absorbance at 562 nm and the amount of reduced Cu
2+
 
is proportional to the amount of total protein present in the samples.  
Duplicates (25 µl) of albumin standards (BSA), samples, and negative control (ddH20) were 
added to a 96-well plate (Thermo Scientific). The samples were diluted 1:5 in ddH20, and the 
BSA standard was diluted in ddH20 at the following concentrations (µg/ml): 1500, 1000, 750, 
500, 250 and 125. The BCA working reagent was prepared by mixing BCA reagent A with 
BCA reagent B (50:1, Reagent A: B) and 200 µl were added to each well. Further, the plate 
was incubated for 30 min at 37°C, and the absorbance was measured at 540 nm for 1 second 
on the plate reader (Modulus microplate). The total protein concentration in the cell lysates 
was calculated from a standard curve based on the absorbance of the albumin standards.  
3.7 Immunoblotting (Western blotting) 
Immunoblotting is used in research to detect specific proteins using antibodies after 
separation by gel electrophoresis.  
According to the total protein concentrations measurements described in chapter 3.6, the cell 
lysates were diluted in ddH20 to obtain chosen amounts of total protein in each loaded sample. 
Subsequently, each diluted samples were mixed with lithium dodecyl sulfate (LDS, replacing 
SDS) (Invitrogen)  and a reducing agent containing dihiothreitol (DTT) (Invitrogen) before 
boiling at 95°C for 5 min. LDS and heating unfolds the protein of interest (i.e. denaturation) 
and gives the proteins a uniform negative charge. DTT helps to further denaturation by 
breaking disulfide bonds that contributes to the three-dimensional structure of proteins. 
Samples, SeeBlue protein standard (Invitrogen) and recombinant human prolegumain (rhLeg) 
(R&D systems) were subsequently loaded on a gradient polyacrylamide gel (4-12 % 
NuPAGE gel, Invitrogen), placed in a gel electrophoresis chamber with MES buffer 
(Appendix 3.1). The electrophoresis was run on 150 V for 1 hour and 15 min. The proteins 
migrate during electrophoresis towards the positive electrode and separate according to size. 
Smaller proteins migrate faster than larger proteins which are delayed in a porous matrix such 
as polyacrylamide gel.  
After separation the proteins were blotted onto a polyvinylidene difluoride (PVDF) (Life 
Technologies) membrane. The membrane is highly hydrophobic and must be activated in 
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methanol (VWR) before soaking in transfer buffer (Appendix 3.2). Whatman paper and 
sponge pads for blotting were also soaked in transfer buffer. The blotting equipment was 
layered in the following order: 3 sponge pads / Whatman paper / gel / membrane / Whatman 
paper / 3 sponge pads. Air bubbles were removed by rolling a pipette over the stack, and the 
equipment was installed into a transfer tank containing transfer buffer. The blotting was done 
at constant current (400 mA) for 1 hour at 4°C.  
To prevent nonspecific bonding of antibodies to the membrane, it was blocked with 5 % dry 
fat-free milk (Tine meierier) TBST-buffer (Tris-Buffered Saline with Tween 20) (Appendix 
3.3) for 1 hour at room temperature with gentle shaking. Subsequently, the membrane was 
incubated with primary antibody for 1 hour and washed 3 times for 10 minutes in TBST 
buffer. Then, the membrane was incubated with secondary antibody for 1 hour and washed 3 
times for 10 minutes in TBST-buffer. The primary antibodies specifically target the proteins 
of interest, and the secondary specifically targets the primary antibody. The antibodies were 
diluted in 5 % dry fat-free milk TBST-buffer, and the used antibodies can be seen in Table 
3.2.  
The secondary antibodies are conjugated with the enzyme horseradish peroxidase (HRP), and 
a chemiluminescent light complex was formed by the addition of SuperSignal West Dura 
Extended Duration Substrate (Pierce). The light was detected by a light sensitive camera 
(G:BOX- Syngene). Image analysis was carried out using GeneSnap and GeneTools. The 
standard, which contains colored proteins of known sizes, was used to estimate the size and to 
identify the proteins on the immunoblots. 
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Table 3.2: Antibodies utilized in immunoblotting.  
Protein Primary antibody Dilution Secondary antibody Dilution 
Legumain Goat anti-human legumain 
polyclonal antibody         
(R&D Systems) 
1:1000 Rabbit Anti-Goat 
immunoglobulins/HRP  
(Dako) 
1:5000 
α –Tubulin Mouse anti-α –tubulin 
monoclonal antibody      
(Calbiochem) 
1:5000 Rabbit Anti-Mouse 
immunoglobulins/HRP   
(Dako) 
1:5000 
Arylsulfatase B 
(ARSB) 
Mouse anti-ARSB 
monoclonal antibody       
(R&D Systems)      
1:500 Rabbit Anti-Mouse 
immunoglobulins/HRP   
(Dako) 
1:5000 
Specificity protein 1 
(SP1) 
Rabbit anti-SP1 polyclonal 
antibody (Millipore) 
1:10000 
 
Goat Anti-Rabbit 
immunoglobulins/HRP  
(Dako) 
1:5000 
3.7.1 Cell viability measurement (MTS) 
The cell viability was measured using the CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (also called MTS assay) (Promega) according to the manufactures protocol. The assay 
contains the tetrazolium compound MTS (3-4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl) and the electron coupling reagent PES (phenazine 
etosulfat). In brief, the MTS compound is reduced by viable cells into to a formazan product. 
The reduction is presumed to be caused by NADPH or NADH produced by dehydrogenase 
enzymes in metabolically active cells. Formazan is a brown colored product, and the quantity 
produced is directly proportional to the number of living cells. 
HCT116 cells were seeded in triplicates in a 96-well plates (Thermo Scientific) with the same 
number of cells in each well (1.4 x 10
4
 cells in a volume of 100 µl), and were incubated 
overnight. The next day, tunicamycin or DMSO was added directly to the cell medium. At the 
day of measurement, 20 µl MTS was added to each well. The cells were incubated for 1 hour, 
and the absorbance was measured 490 nm for 1 second on the plate reader (Modulus 
microplate).  
3.8  Indirect immunofluorescence  
Immunofluorescence is a biochemical labeling technique for detection of specific proteins. 
There are two main methods of immunofluorescence labeling, direct and indirect 
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immunofluorescence. The indirect immunofluorescence method, where the secondary 
antibody is labeled with a fluorochrome, was used in this study to detect legumain, 
endosomes and lysosomes in HCT116 cells. The nucleus was stained with the fluorochrome 
4',6-diamidino-2-phenylindole (DAPI). DAPI intercalates with A-T rich regions of DNA and 
forms a fluorescent complex, and do not require use of a secondary antibody for detection. 
The cells were detected by using a fluorescence microscope (Olympus) and a confocal 
microscope (Carl Zeiss LSM710).  
HCT116 cells were cultured on sterilized glass slides (Thermo scientific) (2.0 x 10
5
/ml) in a 
6-well plate and incubated at 37°C, 5 % C02. To ensure high cell attachment to the glass 
slides, the cells were incubated for two days before treatment with tunicamycin. After 24 
hours, the lysosomes were labeled in live cells using 75 nM Lysotracker Red DND-99 (Life 
technologies) for 1 hour at 37°C. Lysotracker is a permeable fluorescent dye which label 
acidic organelles in live cells.  
The cultured cells were washed 3 times for 5 minutes with cold PBS, fixed for 15 minutes 
with 4 % cold paraformaldehyde (PFA) (Chemi-teknik) (Appendix  4.2), and then washed 3 
times for 5 minutes with 200 mM Hepes (Appendix 4.1) and  3 times for 5 minutes with 1X 
PBS. Subsequently, the cells were permeabilized with 0.2 % Triton-X100 (VWR) (Appendix 
4.5) for 5 minutes and washed 4 times for 5 minutes with 1X PBS, and blocked with 3 % 
horse serum (HS) (Sigma-Aldrich) (Appendix 4.3) at 37°C for 1 hour. After two subsequent 
wash for 5 minutes with 1X PBS and 0.1 % HS (Appendix 4.4), the coverslips were 
transferred to a moisturized incubation chamber. Furthermore, 50 µl primary antibody (Table 
3.3) diluted in 0.1 % HS were added to each coverslips and incubated overnight at 4°C. The 
following day, the coverslips were transferred back to the 6-well plate and washed 6 times for 
5 minutes with 0.1 % HS. Subsequently, the coverslips were incubated  in the moisturized 
incubation camber with diluted secondary antibody (Table 3.3) in 0.1 % HS for 60 minutes at 
37°C, and washed 3 times for 5 minutes with 0.1 % HS. The staining process was repeated 
(using different antibodies, Table 3.3) and the cells were washed 3 times for 5 minutes with 
1X PBS and 1 minute with ddH20. ProLong Gold antifade reagent with DAPI (Life 
technologies) was applied on microscope slides before mounting the coverslips. The slides 
were finally harden for 1 hour at room temperature, and stored at 4°C for further analysis.  
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Table 3.3: Antibodies utilized in immunofluorescences. 
Protein Primary antibody Dilution Secondary antibody Dilution 
Early endosomes 
antigen 1 (EEA1) 
Rabbit EE1-antibody         
(Santa Cruz) 
1:100 Alexa Fluor® 488 donkey 
anti-rabbit antibody                           
(Jackson ImmunoResearch) 
1:300 
Legumain Goat anti-human 
legumain polyclonal 
antibody (R&D systems) 
1:100 Alexa Fluor® 594 donkey 
anti-goat antibody                              
(Jackson ImmunoResearch) 
1:300 
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4 Results 
4.1 Legumain and N-linked glycosylation 
4.1.1 Determination of tunicamycin concentrations and incubation 
time 
To investigate the effect of tunicamycin on HCT116 and SW620 cells, the cells were treated 
with various concentrations of tunicamycin for 6 or 48 hours. The cell morphology and 
legumain expression were analyzed by light microscopy and immunoblotting, respectively.  
Normal cellular morphology was maintained following treatment (not shown). The control 
cells, as well as the tunicamycin-treated cells, were elongated and attached to the well surface.  
Immunoblotting demonstrated that HCT116 and SW620 control cells displayed glycosylated 
prolegumain (56 kDa) and mature legumain (36 kDa), although to a different extent (Fig. 4.1 
A). HCT116 cells expressed mainly mature legumain, while SW620 predominantly expressed 
the proform. In tunicamycin-treated cells, the proform of 56 kDa was converted to a band at 
47 kDa. Demonstrating a noticeable mass shift corresponding to previous studies (Fig. 1.7, 
Haugen et al., unpublished data), indicate the presence of prolegumain without glycan groups 
attached. Moreover, tunicamycin seemed to inhibit glycosylation in a dose- and time-
dependent manner. Increased levels of unglycosylated prolegumain (47 kDa) were observed 
in cells treated with 5 µg/ml tunicamycin for 24 hours, whereas unglycosylated legumain was 
absent or expressed at a very low level when cells were treated under other incubation 
conditions (time/dose) (Fig. 4.1).  
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Figure 4.1: Legumain expression in HCT116 and SW620 cells treated with tunicamycin. (A) The cells were 
treated with tunicamycin using the indicated concentrations and exposure times. The control cells were treated 
with 10 µl DMSO. Protein expression was analyzed by electrophoresis and immunoblotting. All lanes were 
loaded with 25 µg total protein. The filters were stained with a specific antibody against legumain (upper panel) 
and α-tubulin (loading control, lower panel) (n=1). (B) Estimated protein band size of the glycosylated and 
unglycosylated forms of legumain.  
Based on these initial experiments, it was chosen to use a tunicamycin concentration of 5 
µg/ml and exposure length of 24 hours in the following experiments. In addition, we decided 
to focus on the HCT116 cell line. 
4.1.2 Effect of tunicamycin on cell viability  
MTS assay was used to measure cell viability in HCT116 cells after treatment with 0, 2.5 or 5 
µg/ml tunicamycin for 24 hours. The viability of the treated cells relative to control is shown 
in Figure 4.2. Major differences in cell viability between control and tunicamycin-treated cells 
were not observed. 
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Figure 4.2: Cell viability of HCT116 cells treated with tunicamycin. HCT116 cells were treated with 2.5 or 5 
µg/ml tunicamycin and presented relative to control. The control cell was treated with 5 µl DMSO. The figure 
shows the mean values ± SEM (n=3). 
4.1.3 Determination of N-linked glycosylation groups on the 
legumain protein 
It has been identified that mammalian legumain has at least three distinct occupied 
glycosylation seats (Haugen et al., unpublished data, as shown in chapter 1.8.3). Therefore, it 
was of interest to study whether the observed 47 kDa form in tunicamycin-treated cells 
represents fully unglycosylated legumain. The cell lysates were treated with PNGase F, an 
enzyme which removes N-linked glycosylation. Furthermore, it was of interest to determine 
the type of N-linked glycosylation. To investigate this, cell lysates were treated with Endo H, 
which only cleaves the high mannose and hybrid type oligosaccharides.   
HCT116 cells were treated with or without 5 µg/ml tunicamycin for 24 hours, based on the 
results from the initial experiments. The cell lysates were further treated with 1 µl (=500 
units) PNGase or Endo H. Control lysates were added 1 µl ddH20. Legumain expression and 
processing were analyzed by immunoblotting.  
Immunoblotting of cell lysates treated with PNGase F is shown in Figure 4.3 A. HCT116 
control lysates expressed 56 kDa prolegumain and 36 kDa mature legumain, though the latter 
to a higher extent (Fig. 4.3 A). In cells treated with tunicamycin alone, 56 kDa prolegumain 
was converted to 47 kDa prolegumain. Some mature glycosylated legumain of 36 kDa could 
also be observed. PNGase F treatment as well as the combination of tunicamycin and PNGase 
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F resulted in a shift in the apparent molecular mass from 56 kDa to approximately 47 kDa for 
the proform and from 36 kDa to 28 kDa for the mature form of legumain (Fig. 4.3 A), 
although less of the 28 kDa glycosylated mature form was observed in double treated cells. 
The immunoblot demonstrated an identical shift of the molecular mass of glycosylated 
legumain after treatment with PNGase F and the combination with tunicamycin. This 
indicates that legumain is fully unglycosylated upon treatment with 5 µg/ml tunicamycin for 
24 hours.  
Immunoblotting of cell lysates treated with Endo H is shown in Figure 4.3 B. HCT116 control 
lysates expressed 56 kDa prolegumain and 36 kDa mature legumain, though the latter to a 
higher extent (Fig. 4.3 B). In cells treated with tunicamycin alone, 56 kDa prolegumain was 
converted to 47 kDa prolegumain. Some mature glycosylated legumain of 36 kDa could also 
be observed. Endo H treatment as well as the combination of tunicamycin and Endo H 
resulted in a shift in the apparent molecular mass to approximately 47 kDa prolegumain and 
28 kDa mature legumain (Fig. 4.3 B), although less of the 28 kDa glycosylated mature form 
was observed in the double treated cells. Taken together, tunicamycin treatment alone, Endo 
H treatment and the combination, gave identical shifts of the molecular mass of glycosylated 
legumain. The similar shift in molecular mass of legumain from cells treated with PNGase F 
and Endo H indicates that all attached N-glycans are of the high mannose or hybrid types.  
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Figure 4.3: Immunoblot of legumain expression in HCT116 cells when deglycosylated by treatment with 
PNGase F (A) or Endo H (B). HCT116 cells were treated with or without 5 µg/ml tunicamycin. The control 
cells were treated with 10 µl DMSO. After 24 hours the cells were harvested and treated with 500 units PNGase 
F (A) or Endo H (B). Control lysates were added 1µl ddh20. Protein expression was analyzed with 
electrophoresis and immunoblotting. The lanes were loaded with 30 µg (A) or 15 µg (B) total protein. The filters 
were stained with a specific antibody against legumain (upper panel) and α-tubulin (loading control, lower panel) 
(n=1). 
4.1.4 Increased presence of prolegumain in tunicamycin-treated 
HCT116 cells  
The initial experiments demonstrated that processing to non-glycosylated mature legumain 
(28 kDa) were totally absent after tunicamycin treatment for 24 hours. It was therefore of 
interest to examine whether 28 kDa legumain would appear after tunicamycin treatment for a 
prolonged period. We also hypothesized that the presence of glycosylated 36 kDa mature 
legumain was due to the maturation of glycosylated prolegumain synthesized prior to 
treatment. In order to investigate this, HCT116 cells were treated with 5 µg/ml tunicamycin 
for 48 hours. Cell morphology and legumain expression were analyzed by light microscopy 
and immunoblotting, respectively.  
Light microscopy demonstrated that the cellular morphology changed slightly after treatment 
with tunicamycin for 48 hours. The control cells were elongated, while the treated cells 
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seemed smaller with an irregular form. In addition, there were observed multiple detached 
cells following treatment (not shown).   
Legumain processing to the 28 kDa unglycosylated mature form were still not observed after 
treatment for 48 hours with tunicamycin, resulting in an accumulation of the unglycosylated 
proform (47 kDa). Although, small amounts of the glycosylated mature form (36 kDa) were 
still detected in the cell lysates (Fig. 4.4).  
 
Figure 4.4: Legumain expression in HCT116 cells treated with tunicamycin for 48 hours. The cells were 
treated with or without 5 µg/ml tunicamycin. The control cells were treated with 10 µl DMSO. After 48 hours 
the cells were harvested and the protein expression was analyzed by electrophoresis and immunoblotting. Both 
lanes were loaded with 30 µg total protein. The filters were stained with a specific antibody against legumain 
(upper panel) and α-tubulin (loading control, lower panel) (n=1). 
4.1.5 Tunicamycin treatment resulted in altered localization of 
legumain in HCT116 cells 
Having observed cellular accumulation of non-glycosylated prolegumain, it was of interest to 
visualize the distribution of glycosylated versus unglycosylated legumain by 
immunofluorescence confocal microscopy. HCT116 cells were cultured on glass slides, 
treated with or without 5 µg/ml tunicamycin and fixed with PFA. After fixation, the cells 
were stained for legumain and the nucleus. The nucleus was labeled using DAPI, which 
adheres to the double stranded DNA and emits light at 461 nm (blue light). The pseudo-
coloring of the images was performed using software (ZEN 2012). 
Representative confocal pictures of untreated (A) and tunicamycin-treated (B) cells are 
depicted in Figure 4.5. The cell nucleus seemed to be round and intact in both control and 
treated cells (left, top panels). Moreover, the cell shape was also intact and did not show any 
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signs of deformation after treatment (left, lower panels). Thus, the cellular morphology was 
apparently not affected by the tunicamycin treatment. Legumain appeared to be vesicular 
distributed in both untreated and treated cells. Interestingly, there were clear differences 
between legumain expression in treated and untreated cells. Legumain gave rise to more 
intense signal in the treated cells than the untreated, and seemed to be accumulating after 
tunicamycin treatment.  
 
Figure 4.5: Confocal images of legumain in HCT116 cells. The cells were culture on sterile glass slides and 
treated with 10 µl DMSO (A) or 5 µg/ml tunicamycin (B) for 24 hours. After fixation the cells were stained with 
a specific antibody against legumain and with DAPI. The cells were visualized using confocal microscopy with 
63X objective. The merged picture of legumain (green) and the nucleus (blue) are shown to the right. The 
nucleus (white, upper left panels), legumain (white, middle left panels) and phase contrast picture of the cell 
(grey, lower left panels) are shown to the left. Scale bars represent 5 µm. One representative of n=4 experiments 
is shown.   
4.1.6 Expression of unglycosylated legumain in subcellular 
fractions and in conditioned medium  
Legumain is thought to be targeted to and activated in the lysosomes. So far, it is not known 
whether glycosylation is required for transport to the lysosomes. To investigate intracellular 
distribution of unglycosylated legumain, we enriched proteins from various intracellular 
compartments of HCT116 cells treated with or without 5 µg/ml tunicamycin for 24 hours. 
Furthermore, it was also of interest to examine whether secretion was independent of 
glycosylation. To study this, serum free conditioned media derived from HCT116 cells was 
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collected 24 hours after treatment with or without 5 µg/ml tunicamycin. Cell lysates from 
each enriched fraction, total cell lysates and corresponding conditioned growth medium were 
analyzed by immunoblotting for the presence of glycosylated and unglycosylated legumain 
(Fig. 4.6).   
In the cytosolic fraction, small amounts of unglycosylated prolegumain (47 kDa) and 
glycosylated mature legumain (36 kDa) were observed in tunicamycin-treated cell lysates, 
whereas only 36 kDa mature legumain were detected in control lysates. Moreover, HCT116 
control cells displayed low levels of glycosylated proform and high levels of glycosylated 
mature form in the membrane/endo-lysosomal fraction. By comparison, in tunicamycin-
treated cells, substantial amounts of unglycosylated prolegumain (47 kDa) and low levels of 
glycosylated mature legumain (36 kDa) were detected in the membrane/endo-lysosomal 
fraction. In the nucleus fraction, substantial amounts of glycosylated prolegumain and low 
levels of glycosylated active legumain were observed in the control lysates. Interestingly, in 
tunicamycin-treated cell lysates, unglycosylated prolegumain and glycosylated mature 
legumain were expressed at a very low level in the nuclear fraction, which indicate that 
glycosylation is important for legumain transport into the cell nucleus (Fig. 4.6, upper panel).  
Compartment specific protein markers (with presumed limited distribution) were used as 
purity controls. Arylsulfatase B (ARSB) and specificity protein 1 (SP1) were used for the 
membrane/endo-lysosomal and nucleus fractions, respectively. Substantial levels of ARSB 
were found in the membrane/endo-lysosomal fractions, while almost no detectable amounts 
were found in the other fractions (Fig. 4.6, middle panel). The highest level of SP1 was 
detected in the nucleus fractions, and only low levels were detected in the other fractions (Fig. 
4.6, lower panel). The protein markers demonstrated that there was good enrichment of each 
subcellular compartment. 
Glycosylated prolegumain of 56 kDa was found to be secreted and detected in the conditioned 
media derived from untreated HCT116 cells. Of particular interest was the equal presence of 
non-glycosylated prolegumain (47 kDa) in the conditioned media derived from tunicamycin- 
treated cells. Moreover, the mature form was undetectable in conditioned media from both 
treated and untreated cells (Fig. 4.6, upper panel).  
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Figure 4.6: Subcellular localization of legumain from HCT116 cells treated with tunicamycin. The cells 
were treated with 5 µg/ml tunicamycin for 24 hours. The control cells were treated with 10 µl DMSO. Protein 
expression was analyzed by electrophoresis and immunoblotting. The lanes were loaded with 7 µg total protein 
form each intracellular fraction (upper, left panel) or 30 µg total protein from the total cell lysates (upper, right 
panel). Conditioned media was concentrated by acetone- precipitation, and similar volumes were added to the 
lanes (upper, middle panel). The filters were stained with a specific antibody against legumain (upper panels). 
Purity control of the subcellular fractions were assessed by staining for ARSB (soluble lysosomal protein) and 
SP1 (nuclear transcription factor), depicted in middle and lower panels (n=1). 
4.1.7 Endo-lysosomal distribution of unglycosylated legumain?  
Immunofluorescence confocal microscopy was used to visualize whether non-glycosylated 
legumain was transported to the endosomes and lysosomes. Control and tunicamycin-treated 
HCT116 cells were stained for legumain, endosomes, lysosomes and the nucleus. Lysosomes 
were labeled in live cells using Lysotracker, while legumain and the endosomes were stained 
after fixation using a specific antibody against legumain and early endosomes antigen 1 
(EEA1), respectively. The nucleus was labeled using DAPI, and the pseudo-coloring of the 
images was performed using software (ZEN 2012). 
Figure 4.7 represents untreated (A) and tunicamycin-treated (B) cells stained for legumain 
and early endosomes antigen 1 (EEA1). The merged pictures of legumain (red) and EEA1 
(green) are shown in the right panels and some overlap of green and red are seen as yellow 
spots after tunicamycin treatment (B), which may represent colocalization of legumain and 
EEA1. In contrast, overlap of EEA1 (green) and legumain (red), i.e. yellow spots, in the 
control cells were not observed. 
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Confocal microscopy pictures of cells labeled with specific antibody against legumain and 
Lysotracker are depicted in Figure 4.7 C and D. The merged pictures of legumain (red) and 
Lysotracker (green) of untreated (C) and tunicamycin-treated (D) cells showed some overlap 
of red and green colors, i.e. yellow spots, indicating colocalization and thus of legumain in the 
lysosomes.  
Figure 4.7: Endo-lysosomal localization of legumain in HCT116 cells treated with Tunicamycin. HCT116 
cells were cultured on sterile glass slides and treated with 5 µg/ml tunicamycin (B and D) or 10 µl DMSO (A 
and C) for 24 hours. After fixation the cells were stained with specific antibodies and visualized using confocal 
microscopy with 63 X objective. (A and B) Cells stained for the nucleus (blue), legumain (red) and EEA1 
(green). The left panels (from the top) represent legumain, EEA1 and the nucleus. (C and D) Cells stained for the 
nucleus (blue), legumain (red) and Lysotracker (Lyso; green). The left panels (from the top) represent legumain, 
Lysotracker and the nucleus. Scale bars represent 5 µm. One representative of n=3 experiments is shown.  
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4.2 Legumain and phosphorylation 
4.2.1 Effect of protein kinase inhibitors on legumain processing and 
expression 
To investigate the potential connection between legumain processing and phosphorylation, 
HCT116 and SW620 cells were treated with staurosporine, a broad spectrum protein kinase 
inhibitor. Initially the cells were treated with final concentrations of 0, 0.2, 0.6 or 1 µM 
staurosporine for 6 hours.  
The cellular morphology was visualized using light microscopy. The observations are shown 
in Figure 4.8, where cells treated for 6 hours are shown in the upper panels. Morphological 
characteristics of both HCT116 and SW620 cells changed after staurosporine treatment for 6 
hours. Cells treated with staurosporine had an irregular shape, with black and thin branches 
protruding from the cell body. In contrast, there were not observed branches in the control 
cells. Based on these observations, the treatment time was reduced to 0.5 hour (Fig. 4.8, lower 
panels). There were still observed differences in the cell morphology between control and 
staurosporine-treated (1 µM) cells for both cell lines. However, there were also observed 
differences in the cellular morphology of the HCT116 control cells. Control cells after 0.5 
hour treatment were elongated (lower, left panel), whereas the control cells after 6 hours 
treatment were small and non-elongated (top, left panel).  
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Figure 4.8: Effect of staurosporine on the cell morphology of HCT116 and SW620 cells. The cells were 
treated with 1 µM staurosporine for 6 (upper panels) or 0.5 hours (lower panels). The control cells were treated 
with 10 µl DMSO. Morphology of the cells were visualized using light microscopy with 10X (left panels, 
HCT116) or 20X (right panels, SW620) objectives.   
Legumain expression and processing were analyzed by immunoblotting. Immunoblot of the 
cell lysates after staurosporine treatment for 0.5 hour is shown in Figure 4.9 A. In both control 
and staurosporine-treated cells, legumain appeared to be present as prolegumain (56 kDa) and 
mature legumain (36 kDa), although at different levels in HCT116 and SW620 cells as 
previously observed. HCT116 cells expressed mainly mature legumain, while SW620 
expressed higher levels of the proform than the mature form. Similar results were seen after 
treatment for 6 hours (not shown). The immunoblots after staurosporine treatment for 6 and 
0.5 hours gave the impression that there were apparently no alterations in legumain 
expression or processing with or without staurosporine treatment. Total intensities of 
legumain relative to α-tubulin (loading control) following staurosporine treatment are shown 
in Figure 4.9 B (HCT116) and C (SW620). The loading control α-tubulin was used to 
normalize the band intensities of legumain. There were some variations in the total expression 
of legumain between controls and treated cells. However, as the densitometric scanning 
showed that staurosporine gave rise to both increased and decreased total legumain 
expression, it was difficult to draw any conclusions (Fig. 4.9 B and C). 
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Figure 4.9: Legumain processing and expression in HCT116 and SW620 cells treated with staurosporine. 
(A) HCT116 and SW620 cells were treated with staurosporine for 0.5 hour using the indicated concentrations. 
The control cells were treated with 10 µl DMSO. Protein expression was analyzed by electrophoresis and 
immunoblotting. All lanes (except rhLeg) were loaded with 30 µg total protein. The filters were stained with a 
specific antibody against legumain (upper panel) and α- tubulin (lower panel) (n=1). Stauro; Staurosporine. (B 
and C) The graphs shows densitometry measurements (using GeneTools) of the immunoblots with prolegumain 
and mature legumain relative to loading control (α-tubulin) (n=1).   
The experiment was further optimized using H7, a narrow spectrum protein kinase inhibitor. 
The intention, by utilizing a narrow spectrum inhibitor instead of staurosporine, was to obtain 
less adverse cellular processes and changes in the morphology. HCT116 and SW620 cells 
were treated with 0, 5, 15 or 30 µg/ml H7 for 1 hour (Grotterod et al., 2010). Light 
microscopy of the cells demonstrated that, in contrast to staurosporine, H7 did not cause 
alterations in the cellular morphology (not shown). However, immunoblotting showed similar 
legumain expression and processing in control and treated cells, demonstrating that there were 
apparently no change in legumain expression patterns or molecular weight after treatment 
with H7 (Fig. 4.10 A), as reflected by total band intensities of legumain (Fig. 4.10 B and C) 
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Figure 4.10: Legumain processing and expression in HCT116 and SW620 cells treated with H7. (A) 
HCT116 and SW620 cells were treated with H7 for 1 hour using the indicated concentrations. The control cells 
were treated with 10 µl ddH20. Protein expression was analyzed by electrophoresis and immunoblotting. All 
lanes (except rhLeg) were loaded with 20 µg total protein. The filters were stained with a specific antibody 
against legumain (upper panel) and α- tubulin (lower panel) (n=1). (B and C) The graphs shows densitometry 
measurements (using GeneTools) of the immunoblots with prolegumain and mature legumain relative to loading 
control (α-tubulin) (n=1).   
Together, these results demonstrate that inhibition of phosphorylation using either 
staurosporine or H7 did not seem to affect legumain expression or processing. Based on these 
initial data, it was chosen not to continue with experiments investigating further the 
implications of legumain phosphorylation.  
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5 Discussion 
The cysteine proteinase legumain is overexpressed in many solid human tumors and have 
been associated with increased metastatic potential (Liu et al., 2003). Metastasis is the major 
cause of cancer-related deaths, and constitutes a major problem for cancer therapy (Talmadge 
et al., 2010). Cysteine proteinases (in particular legumain) are considered as promising 
candidates to be utilized for cancer specific prodrug targeting (Liu et al., 2003). However, the 
lack of pre-established knowledge has led to failure in similar approaches (Turk, 2006). 
Currently, the knowledge about subcellular localization, trafficking and requirements for 
legumain activation remains largely unexplored. This needs to be revealed before legumain 
are to be utilized for therapeutic intervention. The present study was initiated to reveal the 
importance of legumain glycosylation and phosphorylation, two frequent modifications that 
have been found to play an important role in cellular trafficking and protein function (Farley 
et al., 2009). In this present work we show that glycosylation is necessary for legumain 
maturation and nuclear transport. We also demonstrated that secretion of legumain is 
apparently independent of glycosylation. Additionally, it was demonstrated that manipulation 
of phosphorylation did not affect legumain expression or processing pattern.   
5.1 The choice of cell lines 
The two colorectal cell lines HCT116 and SW620 were used in this study. The choice of these 
cell lines can be explained by two main reasons. First, the cell lines have been found to 
express high levels of endogenous legumain. Second, a substantial difference in their relative 
amount of the pro- and active forms has been observed (Haugen et al., 2013). SW620 express 
high levels of the proform and low levels of the mature form, while the opposite is the case 
for HCT116. Several explanations have been suggested for the differences in legumain 
processing, and thus proteolytic activity between these cell lines. Among other factors, it has 
been hypothesized that altered glycosylation may explain why SW620 exhibits overall less 
mature legumain (Haugen et al., 2013).We observed similar mass shift from glycosylated to 
unglycosylated prolegumain in both cell lines following tunicamycin treatment, thus they both 
seem to be glycosylated. However, an eventual difference in composition of these 
glycosylations remains unexplained. Based on time and work limits, we chose to focus on 
HCT116 in most of our glycosylation experiments. Additionally, HCT116 cells have a larger 
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cytoplasm (previously observed by microscopy), making it more suitable for visualization and 
interpretation by use of immunofluorescence.  
5.2 Legumain and glycosylation 
Before initiating this study, presence of N-linked glycans on legumain was confirmed by our 
research group at the Department of Tumor Biology (Haugen et al., unpublished data, as 
shown in chapter 1.8.2). The asparagine acceptors that are N-linked glycosylated are always 
present in the tripeptide sequence N-X-S/T, were X is any amino acid except proline (Pless et 
al., 1977). In legumain, this specific sequence is present four times (Chen et al., 1997). 
However, it has been demonstrated that this sequence alone is not sufficient for N-linked 
glycosylation. It seems likely that this tripeptide must be accessible in the protein 
conformation, and studies have revealed that approximately one third of the potential sites in 
proteins are actually glycosylated (Kornfeld et al., 1985). Most recently, our research group 
identified that at least three out of the four potential glycosylation sites in legumain seem to 
be occupied (Haugen et al., unpublished data, as shown in chapter 1.8.2). There are three 
main types of N-linked oligosaccharide that can be attached to the target protein termed high 
mannose, complex and hybrid. The three classes all share a common core, but differ in their 
outer chain (Kornfeld et al., 1985, Shandala et al., 2001). By immunoblotting, we found that 
both PNGase treatment and Endo H treatment explicit gave rise to identical shift of the 
apparent molecular mass from 56 to 47 kDa (proform) and from 36 to 28 kDa (mature form) 
of legumain. Thus, we identified that the N-glycans attached to legumain are of the high 
mannose or hybrid types. 
5.2.1 The choice of N-linked glycosylation inhibitor 
N-linked glycosylation is a complex process and involves sequential steps. There are various 
means of interfering with N-linked glycosylation, both in the early and the late stage. In this 
study tunicamycin was employed, a well-used biochemical tool. The advantage to utilize this 
tool was considered to be its specificity towards the common core region present in all N-
linked glycans. Additionally, it was desirable to prevent glycosylation altogether rather than 
using compounds that cause alterations in the structure of the carbohydrate chain (Heifetz et 
al., 1979, Elbein, 1987).   
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In the literature, the amount of tunicamycin described to prevent glycosylation varies between 
0.1 - 10 µg/ml. However, the concentration that can be used is generally limited by its 
toxicity, and the cell line may differ in their susceptibility to this drug (Elbein, 1987). 
Therefore, an optimal concentration needs to be established for every cell line. In the cell lines 
HCT116 and SW620 used herein, a concentration of 5 µg/ml tunicamycin seemed to be an 
optimal concentration to inhibit glycosylation. This concentration was chosen on the basis of 
the observed effect on legumain glycosylation together with low cellular toxicity. 
5.2.2 Effect of N-linked glycosylation on legumain expression, 
processing and localization 
Two molecular forms of legumain were observed in HCT116 lysates treated with 
tunicamycin, and were identified as unglycosylated proform (47 kDa) and glycosylated 
mature form (36 kDa). Of particular interest, the unglycosylated mature form was not 
detected. First, we hypothesize that this might be due to duration of exposure. When 
employing tunicamycin in vitro, it takes a certain time to replace endogenous legumain with 
newly synthesized unglycosylated forms. Additionally, the inactive proenzyme (prolegumain) 
require a multistep processing to reach its mature form (Li et al., 2003). Assuming that both 
of these processes were not completed after the time of exposure used in our experiments, we 
increased the treatment time from 24 to 48 hours. By increasing time of exposure, it also 
seemed reasonable to believe that the formation of the glycosylated mature form would 
disappear due to complete turnover of the initially glycosylated legumain.  
However, by increasing the time of exposure in the HCT116 cell line the unglycosylated 
mature form was still not present. The lack of processing to the mature form resulted in an 
accumulation of the unglycosylated proform. This can partly be explained by the stability of 
legumain. Prolegumain is presumed to be highly stable, whereas mature legumain has a high 
turnover rate (Haugen, personal communication). Thus, when mature legumain is not formed, 
it may be hypothesized that this would lead to accumulation of the proform. Moreover, small 
amounts of the glycosylated mature form were still detected after prolonged tunicamycin 
exposure. It seemed as glycosylated legumain synthesized prior to treatment had a longer 
turnover rate than the longest time of exposure (48 hours) used in our experiments. However, 
a further increased tunicamycin exposure would not be favorable, as this presumably would 
cause several adverse cellular processes such as cell cycle arrest and apoptosis (Savage et al., 
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1983, Elbein, 1987). The treatment time with tunicamycin was limited by its adverse effects. 
Thus, using this method we cannot determine whether a treatment time over 48 hours would 
lead to appearance of the unglycosylated mature form or turnover of endogenous legumain 
synthesized prior to treatment.   
In our experiments, tunicamycin treatment resulted in an accumulation of the proform and no 
detectable mature form (described in previous section), suggesting that inhibition of 
glycosylation had affected the maturation process. We hypothesized that there were two 
explanations for the lack of processing to the unglycosylated mature form:  (1) altered 
trafficking, in which unglycosylated prolegumain is not transported to the lysosomes; or (2) 
legumain is transported to the lysosomes, but not processed to the mature form when 
unglycosylated.  
In the case of our first hypothesis; altered legumain trafficking. Several reports have 
suggested that glycosylation is important in the regulation of protein transport. 
Hemagglutinin, a well characterized viral glycoprotein, is one example where glycosylation 
constitute a key event regulating the transport out of the RER (Copeland et al., 1986, 
Gallagher et al., 1992). There are, however, also reports showing that glycoproteins can be 
transported out of the RER without being glycosylated. For instance fibronectin, which is 
normally glycosylated, although glycosylation is not necessary for secretion or the biological 
activity (Olden et al., 1979, Copeland et al., 1986). The dominant theory for intracellular 
transport of legumain after synthesis is through the Golgi network and further into lysosomes 
through the endosomes. It is assumed that glycosylation is important for transport to the 
lysosomes, which is also the main compartment where inactive prolegumain is thought to be 
processed into the active form of legumain (Chen et al., 2000, Ishidoh et al., 2002, Lecaille et 
al., 2004). Furthermore, the localization of legumain is not strictly lysosomal, it has also been 
observed in other subcellular compartments, such as extracellular and in the nucleus (Liu et 
al., 2003, Haugen et al., 2013). As observed in the HCT116 total lysates (Haugen et al., 
unpublished data, as seen in chapter 1.8.2), secreted and nuclear localized legumain have also 
been found to be glycosylated (Haugen et al., Dept. of Tumor Biology, Oslo University 
Hospital). However, it is not fully known whether and how glycosylation participates in the 
intracellular or extracellular transport of legumain.  
Protein isolation from the intra-organelle membrane fraction of HCT116 cells showed 
presence of unglycosylated prolegumain, but not unglycosylated mature legumain. This is in 
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concurrence with the observation made in total cell lysates. However, the intramembranous 
fraction referred to in this study includes different vesicular structures in the protein transport 
chain, i.e. RER, Golgi, endosomes and the lysosomes. The intention was to study whether 
unglycosylated prolegumain is retrained in RER, Golgi or the endosomes on its route to the 
lysosomes. Therefore, it seemed necessary to utilize methods that separate compartments that 
constitute the intramembranous fraction. One possibility is to use biochemical techniques to 
separate Golgi (by the use of stepwise sucrose gradient centrifugations) from the other 
fractions, and subsequent separate the endosomes from the lysosomes (Sandvig et al., 1991, 
Egeberg et al., 2001) By use of this method we indeed tried to separate Golgi from the other 
intramembranous fractions of HCT116 cells (not shown), however, the results were not 
suitable to draw any conclusions. Another method that can give valuable information on 
subcellular localization is using immunofluorescence confocal microscopy. This was done to 
visualizing the distribution of unglycosylated legumain in early- and late 
endosomes/lysosomes. By confocal microscopy, we observed that unglycosylated legumain 
showed some colocalization with the lysosomes. However, this lysosomal localization needs 
to be supported by biochemical techniques, e.g. the aforementioned compartment separation 
methods, before we can establish evidence that the legumain glycosylation status is not 
important for transport to the lysosomes. In addition, colocalization of glycosylated legumain 
and the lysosomes in untreated HCT116 cells was surprisingly low, implying that the imaging 
techniques requires to be repeated and optimized using other antibodies    
A highly interesting finding was the observed differences in nuclear legumain expression 
between tunicamycin-treated and untreated cells. In line with previous reports, glycosylated 
legumain was found to be highly expressed in the cell nucleus of HCT116 cells (Haugen et 
al., 2013). However, after tunicamycin treatment, nuclear legumain was only present at a 
minor level. Thus, legumain transport into the nucleus seems to be dependent on 
glycosylation. However, how it gains access to the nucleus cannot be determined from these 
results. On the other hand, we showed that both glycosylated and unglycosylated legumain 
were secreted from HCT116 cells. This result indicates that secretion to the extracellular 
environment is apparently independent of glycosylation. It has recently been suggested that 
polyubiquitination of prolegumain promote extracellular secretion, and may regulate whether 
legumain are retrained in the cells or secreted to the environment (Lin et al., 2014). Thus, it 
seems likely that glycosylation and ubiquitination do not influence legumain secretion in the 
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same way. However, detail knowledge concerning the secretory pathway of legumain will 
require further studies.   
In the case of the other formed hypothesis; legumain is transported to the lysosomes, but not 
processed to the mature form when unglycosylated. Legumain is dependent on several events 
to reach its mature form, and it is proposed that lysosomal proteinases are taking part in the 
maturation process (Li et al., 2003). Therefore, we speculate that proteinases only recognize 
and activate the glycosylated form of prolegumain. However, this hypothesis was not tested.  
5.3 Legumain and phosphorylation 
Preliminary data from our research group at the Department of Tumor Biology showed that 
legumain was susceptible to phosphorylation (Haugen et al., unpublished data, shown in 
chapter 1.9.1). However, the positions of the phosphate groups or its function could not be 
interpreted from these results and needed to be further investigated.   
5.3.1 The choice of kinase inhibitors 
To study the role of phosphorylation, HCT1116 and SW620 cells were treated with 
staurosporine. The advantage to utilize this compound was considered to be its inhibitory 
activity towards a broad spectrum of protein kinases. However, we observed morphological 
changes following treatment, even when decreasing time of exposure. Staurosporine is widely 
used to induce apoptosis in a variety of cells. Thus, it seemed reasonable to believe that the 
observed morphological changes were due to apoptosis. As apoptosis itself may influence the 
interpretation of upcoming results, we optimized the experiment using the protein kinase 
inhibitor H7. H7 is more selective and staurosporine, and did not cause apoptosis in neither 
SW620 nor HC116 cells.   
5.3.2 Effect of phosphorylation on legumain processing 
Phosphorylation of proteins turns cellular signaling on and off, and has been shown to be 
important for protein activity (Farley et al., 2009). Protein phosphorylation is catalyzed by 
protein kinases, which have emerged as promising targets used in the clinic (Cohen, 2002). 
By using a broad or narrow spectrum protein kinase inhibitor, we found that there were 
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apparently no variations in legumain processing between control and untreated cells. Thus, 
our experiments point towards that phosphorylation is not important for legumain processing.  
5.4 Methodological considerations 
To support our data, we chose to use both biochemical and imaging analysis techniques. 
Subcellular enrichment, immunoblotting and confocal microscopy are the techniques that 
have formed the basis of many of our results. 
Subcellular enrichment is a biochemical technique which enables isolation and enrichment of 
proteins from different cellular compartments. It is a challenging method, and one important 
limitation is that total purity of the isolated fractions is practically unachievable. In this 
present work, we added washing steps to the protocol (see chapter 3.6) with the aim to limit 
the degree of contamination and to ensure high purity of each fraction. Additionally, 
compartment specific protein markers (proteins of presumed limited distribution) were used 
as purity control in the immunoblot analyses. We chose to utilize protein markers for the 
intramembranous fraction (ARSB) and the nucleus fraction (SP1), as these two fractions 
showed interesting results. The protein markers demonstrated that there were good 
enrichment and purity of the subcellular compartment.  
Confocal microscopy is a well-used imaging technique to visualize different cellular 
components. In this present work we preformed double and triple staining and we spent much 
time trying to find the appropriate primary and secondary antibodies. First of all, multicolor 
staining requires that the primary antibodies have different host species and that the secondary 
antibodies recognize those species exclusively. Second, when using multicolor staining panels 
it is important to eliminate spectral overlap between the fluorochromes. To avoid spectral 
overlap, we utilized secondary antibodies conjugated with fluorochromes which exhibit 
largely separated emission spectra and tune the confocal detectors accordingly. Finally, it was 
also important to choose an appropriate concentration of each antibody. To low concentration 
can result in absent signal, and to high concentration may give rise to unspecific background 
signals. The utilized concentrations were based on the manufactures recommendations and 
experiences within our research group.  
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6 Conclusion  
1) Glycosylation is necessary for legumain processing and activation. 
2) Glycosylation is necessary for intracellular transport of legumain into the nucleus. 
3) Legumain secretion to the extracellular environment is apparently independent of the 
glycosylation status. 
4) Phosphorylation is apparently not important for legumain processing and activation.  
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7 Future perspectives 
The limited time period of this project causes several questions to be left unanswered and 
further investigation and validation is necessary.  
First of all, to confirm the results on the present project, more cell lines and analysis 
techniques needs to be tested. It would be of particular interest reveal the exact localization of 
unglycosylated legumain by both imaging and biochemical techniques. These results may 
give us some further answers to why mature legumain is not formed when the proteinase is 
unglycosylated, and elucidate how glycosylation is necessary for nuclear transport. Another 
important question that should be revealed is how legumain is secreted to the extracellular 
environment.  
An important step would also be to measure legumain activity in HTC116 cells after 
tunicamycin treatment, and to characterize the carbohydrate groups on legumain by mass 
spectroscopy. Furthermore, it would be of interest to determine the position of phosphate 
groups on the legumain protein and to investigate the subcellular localization of legumain 
forms after cell treatment with protein kinase inhibitors.  
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Appendix 
This appendix contains examples and formulas for solutions used in this master thesis.  
1. Cell culture 
1.1 Freezing medium  
For 50 ml freezing medium: 
35 ml Roswell Park Memorial Institute medium (RPMI) 1640 (Sigma-Aldrich) 
10 ml FBS (which constitute 20 % of the final volume) 
5 ml DMSO (which constitute 10 % of the final volume) 
 
1.2 Growth medium (with and without FBS) 
500 ml RPMI 1640  
10 ml Hepes (1 M) (BioWittaker) 
5 ml Glutamax (200 mM) (Invitrogen) 
50 ml FBS 
 
2. Harvesting 
2.1 Lysis buffer (5X)  
For 50 ml lysis buffer: 
1.5 ml NaCl (5 M) 
5 ml Tris-HCl pH 7.5 (0.5 M)  
50 µl NP-40 (0.1 %)  
 
2.2 Lysis buffer (1X) (Working solution) 
0.5 ml lysis buffer (5X) 
0.250 ml Completemini, Proteases inhibitor cocktail (Roche Diagnostics) 
0.250 ml Phosstop, Phosphatase Inhibitor cocktail (Roche Diagnostics) 
1.5 ml H20 (Aqua Braun) 
 
3. Immunoblotting (Westernblotting) 
3.1 MES buffer 
50 ml MES (20X) (Invitrogen) 
950 ml ddH20 
 
3.2 Transfer buffer   
3 g Tris-HCl pH 7.5 (50 mM) (Merck)  
14.4 g Glycine (Merck) 
200 ml Methanol  
Ad 1000 ml ddH20 
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3.3 TBST-buffer  
20 ml Tris-HCl pH 7.5 (1 M) (Life technologies) 
30 ml NaCl (5 M) 
5 ml Tween 20 (20%) (Merck)  
Ad 1000 ml ddH2O 
 
4. Indirect immunofluorescence 
4.1 Hepes (200 mM)  
10 ml Hepes (1 M) 
40 ml pure H20 
 
4.2 Paraformaldehyde (PFA) (4 %) 
0.5 ml PFA (8 %)  
0.5 ml Hepes (200 mM) 
 
4.3 Horse serum (HS) (3 %) 
1 ml HS (100 %)  
32.3 ml PBS (1X) 
 
4.4 HS (0.1 %) 
3.3 ml HS (0.3 %) 
96.7 ml PBS (1X)     
 
4.4 Triton- X100 (10 %) 
2 ml Triton- X100 (100%)  
18 ml PBS (1X) 
 
4.5 Triton- X100 (2 %) (Working solution) 
0.8 ml Triton- X100 (10 %) 
39.2 ml PBS (1X) 
 
 
 
